AAM CEO Leonard Departs After Two Years, Creating Another Trade Group Searching For New Leader
Executive Summary
David Gaugh, AAM’s executive VP of sciences and regulatory affairs, was named the interim CEO, making him the fourth person to run the association since February 2020.
You may also be interested in...
A Bad Fit: Dan Leonard’s Leadership Style Did Not Translate At AAM
Former employees at the Association for Accessible Medicines detail problems that emerged during Leonard’s tenure, but also say the board of directors must improve its management of the trade organization.
A Bad Fit: Dan Leonard’s Leadership Style Did Not Translate At Generics Group
Former employees at the Association for Accessible Medicines detail problems that emerged during Leonard’s tenure, but also say the board of directors must improve its management of the trade organization.
Generic Policy Tweaks In Omnibus Legislation Include Processes Improvements On Late-Stage Label Changes, 505(b)(2) TE Designations
FDA will be able to approve some interchangeable biosimilars more smoothly, but won’t be instructed to provide ANDA sponsors with more information on the inactive ingredients in brand drugs.